Promethera Biosciences SA raised €17 million (US$22.7 million) in a Series B round to fund the first clinical trials of its allogeneic stem cell therapy for pediatric and adult liver disorders. It also received a further €6.6 million in loan financing from Belgium's Walloon region. Read More
Cancer biomarkers have high hopes riding on them, but, so far, low success rates. Of 150,000 biomarkers described in the literature, only about 100 have made it into clinical practice. Read More
Members of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) got a lot to chew on Wednesday as they considered how to assess cardiovascular risks when developing drugs to treat obesity. Read More
• Navidea Biopharmaceuticals Inc. (formerly Neoprobe Corp.), of Dublin, Ohio, said data from its Phase III study of Lymphoseek (99m-Tc-Tilmanocept) in oral and squamous cell cancers suggested the radiopharmaceutical improves identification of primary draining nodes to properly stage patients with head and neck squamous cell cancers using sentinel lymph node mapping. Read More
• IntelliCell BioSciences Inc., of New York, said it received a warning letter dated March 13 from the FDA related to an inspection carried out between Nov. 8, 2011, and Dec. 12, 2011. Read More
• Allergan Inc., of Irvine, Calif., said two Phase III trials of Botox (onabotulinumtoxinA) met their primary endpoints in overactive bladder, with data from both studies showing that Botox significantly reduced urinary incontinence episodes compared to placebo in patients not adequately managed by an anticholinergic treatment. Read More
